Christensen N J, Trap-Jensen J, Svendsen T L, Rasmussen S, Nielsen P E
Eur J Clin Pharmacol. 1978 Dec 1;14(4):227-30. doi: 10.1007/BF00560454.
Injection i.v. of labetalol, a new adrenergic alpha- and beta-blocking agent, decreased arterial blood pressure in 9 hypertensive subjects resting in the supine position, when standing and during supine exercise. Heart rate after labetalol was unchanged in the resting supine position, and it fell in the latter two conditions. Plasma noradrenaline concentration was higher after labetalol in all three experiments as compared to a control study. Plasma adrenaline after labetalol was increased only in the standing position, when the highest plasma noradrenaline concentrations were observed. Blood glucose concentration tended to increase after labetalol, but the difference was not statistically significant. The changes in plasma noradrenaline and blood glucose after labetalol mimic findings observed after alpha-adrenergic receptor blockade. The beta-adrenergic receptor blocking property of labetalol is responsible for the reduced heart rate and it is likely to contribute to the higher plasma noradrenaline concentration observed when standing and during supine exercise.
静脉注射新型肾上腺素α和β受体阻滞剂拉贝洛尔,可使9名仰卧位休息、站立及仰卧位运动的高血压患者的动脉血压降低。在仰卧位休息时,注射拉贝洛尔后的心率未变,而在站立及仰卧位运动这两种情况下心率下降。与对照研究相比,在所有三项实验中,注射拉贝洛尔后的血浆去甲肾上腺素浓度均较高。注射拉贝洛尔后,仅在站立位时血浆肾上腺素升高,此时观察到最高的血浆去甲肾上腺素浓度。注射拉贝洛尔后血糖浓度有升高趋势,但差异无统计学意义。注射拉贝洛尔后血浆去甲肾上腺素和血糖的变化与α肾上腺素能受体阻断后观察到的结果相似。拉贝洛尔的β肾上腺素能受体阻断特性导致心率降低,并且可能是站立及仰卧位运动时血浆去甲肾上腺素浓度升高的原因。